The effect of PTH(1-84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: results of a randomized, open-label clinical trial.

Quesada-Gómez JM, Muschitz C, Gómez-Reino J, Greisen H, Andersen HS, Dimai HP

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA30 Oct 2010Cited by 13 (Europe PMC)

PMID21052638DOI10.1007/s00198-010-1460-6PepBankPUB-21052638

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal osteoporosis, PTH increased P1NP percentage change from baseline more than strontium ranelate by week 24 (p < 0.0001).
In plain wordsIn postmenopausal osteoporosis, PTH increased P1NP more than strontium ranelate by week 24.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseP1NP change at week twenty-four
Study
n = 81
Comparator
Strontium ranelate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 μg daily · subcutaneous injection · 24 weeksAs given in this study (human).
Source sentences
Summary
Percentage changes from baseline in P1NP and BSAP were significantly increased for PTH(1-84) by week 24 compared with SR (p < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
A 24-week, randomized, open-label, parallel group, phase IV trial was conducted in 81 postmenopausal women with primary osteoporosis (≥50 years of age, lumbar spine, or total hip T-score ≤-2.5 SD) to assess the effect of SR as compared to PTH(1-84) on bone formation markers P1NP and BSAP.
Summary · context
Subjects were randomly assigned to receive daily either 100 μg PTH(1-84) (n = 41) (subcutaneous injection) or oral 2 g SR (n = 40) for 24 weeks with daily supplements of 800 IU vitamin D(3) and 1,000 mg calcium.
Report a problemFND-2105263801
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal osteoporosis, PTH increased BSAP percentage change from baseline more than strontium ranelate by week 24 (p < 0.0001).
In plain wordsIn postmenopausal osteoporosis, PTH increased BSAP more than strontium ranelate by week 24.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseBSAP change at week twenty-four
Study
n = 81
Comparator
Strontium ranelate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 μg daily · subcutaneous injection · 24 weeksAs given in this study (human).
Source sentences
Summary
Percentage changes from baseline in P1NP and BSAP were significantly increased for PTH(1-84) by week 24 compared with SR (p < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
A 24-week, randomized, open-label, parallel group, phase IV trial was conducted in 81 postmenopausal women with primary osteoporosis (≥50 years of age, lumbar spine, or total hip T-score ≤-2.5 SD) to assess the effect of SR as compared to PTH(1-84) on bone formation markers P1NP and BSAP.
Summary · context
Subjects were randomly assigned to receive daily either 100 μg PTH(1-84) (n = 41) (subcutaneous injection) or oral 2 g SR (n = 40) for 24 weeks with daily supplements of 800 IU vitamin D(3) and 1,000 mg calcium.
Report a problemFND-2105263802
03HumanNon-randomized trialEfficacy outcome
In postmenopausal osteoporosis, P1NP changed significantly from baseline from week 4 onwards during PTH treatment.
In plain wordsIn postmenopausal osteoporosis, P1NP changed significantly from baseline from week 4 onwards during PTH treatment.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseP1NP change from week four
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 μg daily · subcutaneous injectionAs given in this study (human).
Source sentences
Summary
Significant changes from baseline in P1NP and BSAP were noted for PTH(1-84) from week 4 onwards; no significant changes were noted for SR.
3 context sentences(design, population, supporting numbers)
Summary · context
Biochemical markers of bone formation were significantly increased after treatment with PTH(1-84) but not strontium ranelate, indicating a different mechanism of action between these agents.
Summary · context
A 24-week, randomized, open-label, parallel group, phase IV trial was conducted in 81 postmenopausal women with primary osteoporosis (≥50 years of age, lumbar spine, or total hip T-score ≤-2.5 SD) to assess the effect of SR as compared to PTH(1-84) on bone formation markers P1NP and BSAP.
Summary · context
Subjects were randomly assigned to receive daily either 100 μg PTH(1-84) (n = 41) (subcutaneous injection) or oral 2 g SR (n = 40) for 24 weeks with daily supplements of 800 IU vitamin D(3) and 1,000 mg calcium.
Report a problemFND-2105263803
04HumanNon-randomized trialEfficacy outcome
In postmenopausal osteoporosis, BSAP changed significantly from baseline from week 4 onwards during PTH treatment.
In plain wordsIn postmenopausal osteoporosis, BSAP changed significantly from baseline from week 4 onwards during PTH treatment.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseBSAP change from week four
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 μg daily · subcutaneous injectionAs given in this study (human).
Source sentences
Summary
Significant changes from baseline in P1NP and BSAP were noted for PTH(1-84) from week 4 onwards; no significant changes were noted for SR.
3 context sentences(design, population, supporting numbers)
Summary · context
Biochemical markers of bone formation were significantly increased after treatment with PTH(1-84) but not strontium ranelate, indicating a different mechanism of action between these agents.
Summary · context
A 24-week, randomized, open-label, parallel group, phase IV trial was conducted in 81 postmenopausal women with primary osteoporosis (≥50 years of age, lumbar spine, or total hip T-score ≤-2.5 SD) to assess the effect of SR as compared to PTH(1-84) on bone formation markers P1NP and BSAP.
Summary · context
Subjects were randomly assigned to receive daily either 100 μg PTH(1-84) (n = 41) (subcutaneous injection) or oral 2 g SR (n = 40) for 24 weeks with daily supplements of 800 IU vitamin D(3) and 1,000 mg calcium.
Report a problemFND-2105263804
05HumanNon-randomized trialEfficacy outcome
In postmenopausal osteoporosis, PTH treatment showed a trend toward a positive effect on quality of life.
In plain wordsIn postmenopausal osteoporosis, PTH treatment showed a trend toward better quality of life.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
Direction not reportedQuality of life
Study
n: not reported in source
Outcome group
Quality of life · Whole body
Studied dose
100 μg daily · subcutaneous injection · 24 weeksAs given in this study (human).
Source sentences
Summary
A trend towards a positive impact on QoL was seen with PTH(1-84) treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
A 24-week, randomized, open-label, parallel group, phase IV trial was conducted in 81 postmenopausal women with primary osteoporosis (≥50 years of age, lumbar spine, or total hip T-score ≤-2.5 SD) to assess the effect of SR as compared to PTH(1-84) on bone formation markers P1NP and BSAP.
Summary · context
Subjects were randomly assigned to receive daily either 100 μg PTH(1-84) (n = 41) (subcutaneous injection) or oral 2 g SR (n = 40) for 24 weeks with daily supplements of 800 IU vitamin D(3) and 1,000 mg calcium.
Report a problemFND-2105263805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.